{"id":6052,"date":"2025-03-22T17:08:14","date_gmt":"2025-03-22T14:08:14","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=6052"},"modified":"2025-03-22T17:08:14","modified_gmt":"2025-03-22T14:08:14","slug":"finerenones-effects-in-hfmref-hfpef-and-obesity","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/finerenones-effects-in-hfmref-hfpef-and-obesity\/","title":{"rendered":"Finerenone\u2019s Effects in HFmrEF\/HFpEF and Obesity"},"content":{"rendered":"
Summary: Finerenone\u2019s Effects in HFmrEF\/HFpEF and Obesity<\/div>\n
<\/div>\n
Source: Butt JH, Henderson AD, Jhund PS, et al. J Am Coll Cardiol. 2025, j.jacc. (AHA highlited in 12 March2025.)<\/div>\n
1. Study Background:<\/span><\/div>\n
\u2022 Obesity is associated with increased aldosterone secretion, which may influence heart failure (HF) progression.<\/span><\/div>\n
\u2022 Finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), was shown to reduce cardiovascular (CV) death and worsening HF events in HF with mildly reduced\/preserved ejection fraction (HFmrEF\/HFpEF) in the FINEARTS-HF trial.<\/span><\/div>\n
2. Study Design & Methods:<\/span><\/div>\n
\u2022 Phase 3, international, double-blind, placebo-controlled RCT.<\/span><\/div>\n
\u2022 6,001 HFmrEF\/HFpEF patients with LVEF \u226540%, NYHA class II\u2013IV, and elevated NT-proBNP randomized to finerenone or placebo.<\/span><\/div>\n
\u2022 Median follow-up: 32 months.<\/span><\/div>\n
\u2022 Patients stratified by BMI categories: underweight\/normal weight (<25 kg\/m\u00b2), overweight (25.0\u201329.9 kg\/m\u00b2), obesity class I (30.0\u201334.9 kg\/m\u00b2), and obesity class II\/III (\u226535.0 kg\/m\u00b2).<\/span><\/div>\n
3. Clinical Outcomes by BMI:<\/span><\/div>\n
\u2022 Obesity class II\/III patients had higher risks of CV death or worsening HF events (WHFEs) compared to underweight\/normal-weight individuals.<\/span><\/div>\n
\u2022 Overweight and obesity class I patients had no significant difference in primary endpoint risk but had a lower risk of all-cause mortality.<\/span><\/div>\n
\u2022 In fully adjusted models, BMI \u226530 kg\/m\u00b2 was associated with a higher primary endpoint risk, while the mortality benefit disappeared.<\/span><\/div>\n
4. Efficacy of Finerenone:<\/span><\/div>\n
\u2022 Finerenone reduced the risk of CV death or WHFEs regardless of BMI.<\/span><\/div>\n
\u2022 Patients with higher BMI seemed to derive a greater benefit.<\/span><\/div>\n
\u2022 No significant interaction was observed between BMI and the treatment effect on secondary endpoints.<\/span><\/div>\n
5. Conclusion:<\/span><\/div>\n
\u2022 Finerenone effectively reduced CV death and WHFEs in HFmrEF\/HFpEF patients, irrespective of BMI.<\/span><\/div>\n
\u2022 Higher BMI patients may experience greater benefits.<\/span><\/div>\n
\u2022 The study found no consistent evidence supporting the \u201cobesity-survival paradox\u201d in HF.<\/span><\/div>\n
https:\/\/doi.org\/10.1016\/j.jacc.2024.10.111<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Summary: Finerenone\u2019s Effects in HFmrEF\/HFpEF and Obesity Source: Butt JH, Henderson AD, Jhund PS, et al. J Am Coll Cardiol. 2025, j.jacc. (AHA highlited in 12 March2025.) 1. Study Background: \u2022 Obesity is associated with increased aldosterone secretion, which may influence heart failure (HF) progression. \u2022 Finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), was shown […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6052","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6052","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=6052"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6052\/revisions"}],"predecessor-version":[{"id":6053,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6052\/revisions\/6053"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=6052"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=6052"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=6052"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}